Latham.London

Category Archives: Life Sciences

Subscribe to Life Sciences RSS Feed

COVID-19: DHSC and MHRA Pave the Way for Increased Ventilator Production

UK companies interested in producing ventilators and other critical equipment may benefit from regulatory exemptions and use government product specifications. By Frances Stocks Allen and Oliver Mobasser On 16 March 2020, Prime Minister Boris Johnson called on the UK’s leading manufacturing businesses to help the UK step up production of vital medical equipment to combat … Continue Reading

New EU Medical Devices Regulation to Be Postponed Until 2021

European Commission proposes one-year postponement in light of the COVID-19 crisis. By Frances Stocks Allen and Oliver Mobasser On 25 March 2020, the European Commission announced that it was working on a proposal to postpone the date of application for the new EU Medical Devices Regulation (MDR)[i] for one year, in light of the COVID-19 … Continue Reading

Green Shoots for the Commercialisation of Cannabis-Based Medicinal Products in the UK?

By Frances Stocks Allen and Oliver Mobasser Recent legal and regulatory developments pave the way for an increased commercialisation opportunity in cannabis-based medicines, but complex rules require careful navigation. The National Institute for Health and Care Excellence (NICE) recommended the reimbursement of two plant-derived cannabis products for the first time on 10 November 2019. This … Continue Reading

MHRA Releases No-Deal Brexit Guidance for Life Sciences Companies

The guidance provides helpful clarity on key regulatory changes impacting life sciences companies in the event of a no-deal Brexit. By Frances Stocks Allen, Oliver Mobasser, Héctor Armengod, Gail E. Crawford, Christoph W.G. Engeler, Robbie McLaren, and Henrietta J. Ditzen The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a significant volume of … Continue Reading
LexBlog